Segmentation: biosimilars in oncology & immunology

pills different colours

Understanding physicians perceptions around the use of biosimilars and the drivers for use, RA Partners interviewed different physician specialities to understand if prescribing choice is driven by reasons beyond financial considerations and what the expectations of efficacy are for this new and growing market. The division in opinion between those who believe “why prescribe panadol instead of paracetamol” to others who believe that biosimilars offer no tangible benefit beyond branded products so why prescribe biosimilars and take a risk, was stark. A market that needs clear segmentation.